Company profile
Regencell Bioscience Holdings Limited (RGC)
Free on iOS and Android.
About Regencell Bioscience Holdings Limited
from the company's filings and listing, as of Oct 25, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Chief executive
- Yat-Gai Au
- Employees
- 10
- Listed since
- Jul 16, 2021
- Market value
- $3.8B
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$0.02
- Dividend yield
- -
Earnings
6 reported quarters · next on Oct 28, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Jun 15, 2026 | -$0.01 | n/a | n/a | n/a | EPS n/aRevenue n/a |
| Nov 18, 2025 | $0.00 | n/a | n/a | n/a | EPS n/aRevenue n/a |
| Jun 26, 2025 | -$0.14 | n/a | n/a | n/a | EPS n/aRevenue n/a |
| Oct 25, 2024 | $0.00 | n/a | n/a | n/a | EPS n/aRevenue n/a |
| Q2 FY2024reported Jan 26, 2024 | $0.00 | n/a | n/a | n/a | EPS n/aRevenue n/a |
| Oct 27, 2023 | -$0.01 | n/a | n/a | n/a | EPS n/aRevenue n/a |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| Geode Capital Management, LLC | $2.6M | 422,011 | +1.6% | 0.09% |
| Alyeska Investment Group, L.P. | $2.5M | 416,261 | New | 0.08% |
| Legal & General Group PLC | $779K | 128,000 | +1192.5% | 0.03% |
| Jane Street Group, LLC | $599K | 98,348 | New | 0.02% |
| XTX Topco Ltd | $366K | 60,061 | New | 0.01% |
| Amundi | $287K | 47,159 | +448.7% | 0.01% |
| UBS Group AG | $263K | 43,208 | +80.9% | 0.01% |
| Quadrature Capital Ltd | $254K | 41,750 | New | 0.01% |
| Susquehanna International Group, LLP | $141K | 23,129 | New | 0.00% |
| Squarepoint Ops LLC | $134K | 22,036 | -17.2% | 0.00% |
| Fox Run Management, L.L.C. | $126K | 20,691 | New | 0.00% |
| CIBC Asset Management Inc | $93K | 15,292 | New | 0.00% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Questions
Why are no insider or congress trades shown for RGC?
This page lists no open-market insider filing and no congressional disclosure in Regencell Bioscience Holdings Limited. A congressional disclosure names a company by its ticker symbol alone, and a symbol can be reassigned after its previous holder leaves the market. 6 disclosures filed under RGC are dated before this company began trading under it, and are not shown here. The filing tables appear as filings are published.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.
Related companies
also in HealthcareGetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.